Drug development

DDL-920 Reversing the Symptoms of Alzheimer’s Disease

NEW YORK – DDL-920 Reversing the Symptoms of Alzheimer's Disease could mark a significant breakthrough in the treatment of this debilitating condition. While current therapies primarily focus on targeting the physical manifestations of Alzheimer's, such as amyloid plaques, a new approach is emerging. Rather than concentrating on combating the plaques associated with Alzheimer's disease, researchers

By |2024-08-18T16:52:09-04:00August 11th, 2024|Featured, Life Sciences, Life Sciences/Biotech|

Anti-Aging Drug Boosts Lifespan By 25 Percent While Preventing Cancer And Gray Hair

Have you ever wished you could slow down the ticking clock of aging? Science might have come a smidgen closer to granting your wish. Researchers have developed a new anti-aging drug that claims to significantly increase lifespan, adding up to 25% more healthy, vibrant years. The brain behind this exciting development is none other than

By |2024-07-23T18:43:45-04:00July 21st, 2024|Featured, Life Sciences, Life Sciences/Biotech|

Esperion’s New Cholesterol-Busting Drug Hits The Market

ANN ARBOR—After years of development, Nexletol, the new cholesterol-reducer from Ann Arbor’s Esperion Therapeutics Inc., is now on the market and available in pharmacies in the United States. Nexletol uses a new mechanism of action to reduce low-density lipoprotein (LDL-C), the so-called bad cholesterol in the bloodstream, the cholesterol that can cause arterial blockages that

Esperion Names Biotech Veteran Jay Shepard To Board

ANN ARBOR — Pharma startup Esperion Therapeutics announced this week the appointment of Jay P. Shepard as a Class III Director, with a term expiring at the 2019 annual meeting of stockholders. “Jay’s experience supporting the launch and commercialization of biopharmaceutical products will be invaluable as we advance the bempedoic acid product franchise through the

By |2018-06-01T11:44:44-04:00June 1st, 2018|ESD, Life Sciences, Life Sciences/Biotech|

Esperion Starts Phase 3 Study of Cholesterol-Fighter

ANN ARBOR — Esperion Therapeutics Inc. Monday announced the start of a Phase 3 study to assess the safety and efficacy of a combination pill containing its cholesterol-fighter, bempedoic acid, with ezetimibe, a drug that decreases cholesterol absorption in the small intestine. Ezetimibe is used when other cholesterol-lowering medications, such as statins, are not tolerated

By |2017-11-08T11:38:20-05:00November 8th, 2017|ESD, Life Sciences|